The company uses its proprietary development platform Humabody to develop novel therapies which is claims have "superior biophysical properties".

The company's pipeline is led by CB307, a novel bispecific tumour-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity.

Investors in Crescendo include Astellas and Takeda as well as VC firms such as Quan Capital.